688363-66-8

Basic information

• Product Name: 1-BOC-2,6-DIMETHYL-PIPERAZINE
• Synonyms: 1-BOC-2,6-DIMETHYL-PIPERAZINE;tert-butyl 2,6-diMethylpiperazine-1-carboxylate;1-Boc-2,6-diMethylpiperaz...;1-Piperazinecarboxylic acid, 2,6-diMethyl-, 1,1-diMethylethyl ester;2,6-Dimethyl-1-piperazinecarboxylic acid tert-butyl ester
• CAS NO: 688363-66-8
• Molecular Formula: C11H22N2O2
• Molecular Weight: 214.3
• Mol File: 688363-66-8.mol

Chemical Properties

• Boiling Point: 279.7±15.0 °C(Predicted)
• Appearance: /
• Density: 0.970±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.53±0.60(Predicted)
• CAS DataBase Reference: 1-BOC-2,6-DIMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-2,6-DIMETHYL-PIPERAZINE(688363-66-8)
• EPA Substance Registry System: 1-BOC-2,6-DIMETHYL-PIPERAZINE(688363-66-8)

Safety Data

• Hazardous Substances Data: 688363-66-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
1-BOC-2,6-DIMETHYL-PIPERAZINE is used as a synthetic intermediate for the preparation of various organic compounds due to its piperazine ring structure. This allows for the creation of a wide range of chemical products with diverse applications.
Used in Pharmaceutical Industry:
1-BOC-2,6-DIMETHYL-PIPERAZINE is used as a building block in the synthesis of pharmaceutical compounds, particularly those that require the piperazine ring for their biological activity. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic benefits.
Used in Research and Development:
1-BOC-2,6-DIMETHYL-PIPERAZINE is used as a research chemical in academic and industrial laboratories, where it can be employed to study the properties and reactions of piperazine-containing compounds. This can lead to the discovery of new chemical reactions and the development of novel applications in various fields.

Upstream product

• 108-49-6 3,5-dimethylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1207455-37-5 benzyl 4-(t-butoxycarbonyl)-3,5-dimethylpiperazine-1-carboxylate 
• 2080367-38-8 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 623585-97-7 benzyl (3S,5R)-3,5-dimethylpiperazine-1-carboxylate 

Downstream Products

• 1610520-52-9 tert-butyl 4-((7-(3,4-dimethoxyphenyl)-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridin-2-yl)methyl)-2,6-dimethylpiperazine-1-carboxylate 

Relevant articles and documents

JAK1 SELECTIVE INHIBITORS

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.